Patents by Inventor Ross Stephens
Ross Stephens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230255992Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRO). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g.Type: ApplicationFiled: February 6, 2023Publication date: August 17, 2023Applicants: The Australian National University, Griffith UniversityInventors: Christopher Parish, Connor O'Meara, Lucy Coupland, Benjamin Ju Chye Quah, Farzaneh Kordbacheh, Anna Orlov, Anna Browne, Ross Stephens, Gregory David Tredwell, Lee Andrew Philip, Karen Knox, Laurence Mark von Itzstein, Chih-Wei Chang, Anne Brüstle, David Anak Simon Davis
-
Patent number: 11628179Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Type: GrantFiled: December 14, 2018Date of Patent: April 18, 2023Assignees: The Australian National University, Griffith UniversityInventors: Christopher Parish, Connor O'Meara, Lucy Coupland, Benjamin Ju Chye Quah, Farzaneh Kordbacheh, Anna Orlov, Anna Browne, Ross Stephens, Gregory David Tredwell, Lee Andrew Philip, Karen Knox, Laurence Mark von Itzstein, Chih-Wei Chang, Anne Brüstle, David Anak Simon Davis
-
Publication number: 20220168327Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Type: ApplicationFiled: February 25, 2019Publication date: June 2, 2022Inventors: Christopher Parish, Connor O'Meara, Lucy Coupland, Benjamin Ju Chye Quah, Farzaneh Kordbacheh, Anna Bezos, Anna Browne, Ross Stephens, Gregory David Tredwell, Lee Andrew Philip, Karen Knox, Laurence Mark von Itzstein, Chih-Wei Chang, Anne Brüstle, David Anak Simon Davis
-
Publication number: 20210205343Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Type: ApplicationFiled: December 14, 2018Publication date: July 8, 2021Inventors: Christopher Parish, Connor O'Meara, Lucy Coupland, Benjamin Ju Chye Quah, Farzaneh Kordbacheh, Anna Bezos, Anna Browne, Ross Stephens, Gregory David Tredwell, Lee Andrew Philip, Karen Knox, Laurence Mark von Itzstein, Chih-Wei Chang, Anne Brüstle, David Anak Simon Davis
-
Publication number: 20160151518Abstract: The invention relates to a radiolabelled material comprising a polymer, a radioactive isotope, and an immobilizing agent, wherein the immobilizing agent is capable of immobilizing the radioactive isotope on or in the polymer, and wherein the immobilizing agent is a macromolecule comprising electron donating groups. The invention also relates to a process for making a radiolabelled material, to use of a radiolabelled material for the preparation of medicaments for treating cancer and/or for radiation imaging, and to use of a radiolabelled material in the treatment of cancer. There is further described use of an immobilizing agent to immobilize a radioactive isotope on or in a polymer.Type: ApplicationFiled: December 20, 2013Publication date: June 2, 2016Inventors: Ross Stephens, Jessica Louise Bell
-
Patent number: 8061746Abstract: A mango fruit holder consists of a sharpened pair of tines extending from a grip handle. A pommel is located in the handle at the end opposite the tines, with a pair of tangs extending from and forming part of the tines through the handle into abutment with the pommel. Impact blows directed against the pommel are thereby efficiently transmitted through the tangs to the sharpened tines, assisting the penetration of the hardened mango seed by the tines. By temporarily anchoring the tines within the mango seed a user is able to use the handle to hold the mango while peeling and removing the edible mango flesh.Type: GrantFiled: November 28, 2008Date of Patent: November 22, 2011Inventor: Ross Stephens, III
-
Patent number: 7807379Abstract: The present invention describes a method for determining whether an individual is likely to suffer from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.Type: GrantFiled: June 9, 2006Date of Patent: October 5, 2010Assignee: RigshospitaletInventors: Mads Holten-Andersen, Ross Stephens, Hans Jørgen Nielsen, Ib Jarle Christensen, Nils Brünner
-
Publication number: 20080171691Abstract: Invasive remodelling in a mammal may be inhibited by (1) inhibiting or abolishing the protein cleaving action of plasmin and (2) inhibiting or abolishing the protein cleaving action of at least one additional proteolytic enzyme active in invasive remodelling, such as a metalloprotease.Type: ApplicationFiled: January 24, 2008Publication date: July 17, 2008Inventors: Leif Roge Lund, Keld Dano, Ross Stephens, Nils Brunner, Helene Solberg, Claus Holst-Hansen, John Romer Nielsen
-
Publication number: 20070020707Abstract: The present invention describes a method for determining whether an individual is likely to have cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.Type: ApplicationFiled: June 9, 2006Publication date: January 25, 2007Applicant: RigshospitaletInventors: Mads Holten-Andersen, Ross Stephens, Hans Jorgen Nielsen, Ib Christensen, Nils Brunner
-
Publication number: 20070009430Abstract: A method for forming an inhalable isotope compound suitable for use in patient medical diagnosis, the method comprising the steps of: (a) electrolytic loading of a carbon crucible with the isotope; (b) sublimating any isotope carrier in the crucible; (c) ablating the isotope in a carbon crucible, forming an ablation aerosol; (d) directly delivering the aerosol for immediate use by a patient. The isotope can comprise technetium.Type: ApplicationFiled: February 24, 2006Publication date: January 11, 2007Inventors: Rodney Browitt, William Burch, Timothy Senden, Ross Stephens, David Shaw
-
Patent number: 7026282Abstract: A novel set of inhibitors of the binding interaction between human urokinase plasminogen activator (uPA) and its cell surface receptor (uPAR) has been developed. The inhibitors comprise of peptide fragments, monomeric or in multiple copies attached to a common scaffold, in which the amino acid sequence may include uncommon substituted amino acids to partially comprise of peptoid sequences. The present invention also relates to the use of such peptides in therapy, in particular for the treatment of cancer, having developed a modified non-human mammalian receptor to which the novel inhibitors are antagonistic.Type: GrantFiled: July 1, 1999Date of Patent: April 11, 2006Assignee: Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning)Inventors: Michael Ploug, Søren Østergaard, Claus Holst-Hansen, Ross Stephens, Keld Danø, Arne Holm
-
Publication number: 20050137121Abstract: Invasive remodelling in a mammal may be inhibited by (1) inhibiting or abolishing the protein cleaving action of plasmin and (2) inhibiting or abolishing the protein cleaving action of at least one additional proteolytic enzyme active in invasive remodelling, such as a metalloprotease.Type: ApplicationFiled: September 29, 2004Publication date: June 23, 2005Inventors: Leif Lund, Keld Dano, Ross Stephens, Nils Brunner, Helene Solberg, Claus Holst-Hansen, John Nielsen
-
Patent number: 6795798Abstract: A system and method for analyzing a process collects process data within a process control plant and transmits the collected process data to a remote data processing facility. The remote data processing facility analyzes the process data using a process analysis tool such as a process monitoring tool, an equipment monitoring tool, a device monitoring tool, an index generation tool, a work order generation tool and/or an accounting tool to generate analysis data. The analysis data is then transmitted to the process control plant via a communication link such as the Internet.Type: GrantFiled: May 10, 2001Date of Patent: September 21, 2004Assignee: Fisher-Rosemount Systems, Inc.Inventors: Evren Eryurek, Ross Stephen Smith, Ian Bryce Dewar, Stuart Brian Raynor, Jeffrey Alan Minto
-
Publication number: 20020123864Abstract: A system and method for analyzing a process collects process data within a process control plant and transmits the collected process data to a remote data processing facility. The remote data processing facility analyzes the process data using a process analysis tool such as a process monitoring tool, an equipment monitoring tool, a device monitoring tool, an index generation tool, a work order generation tool and/or an accounting tool to generate analysis data. The analysis data is then transmitted to the process control plant via a communication link such as the Internet.Type: ApplicationFiled: May 10, 2001Publication date: September 5, 2002Inventors: Evren Eryurek, Ross Stephen Smith, Ian Bryce Dewar, Stuart Brian Raynor, Jeffrey Alan Minto
-
Publication number: 20020099004Abstract: Invasive remodelling in a mammal may be inhibited by (1) inhibiting or abolishing the protein cleaving action of plasmin and (2) inhibiting or abolishing the protein cleaving action of at least one additional proteolytic enzyme active in invasive remodelling, such as a metalloprotease.Type: ApplicationFiled: November 29, 2001Publication date: July 25, 2002Inventors: Leif Roge Lund, Keld Dano, Ross Stephens, Nils Brunner, Helene Solberg, Claus Holst-Hansen, John Romer Nielsen